ERBB2 and ductal breast carcinoma in situ: Another limitation of this study was the fact that SUM-225 cells utilized in the three in vivo models represented only ER-negative HER2-positive tumors, thus providing no insight into the ~70% of DCIS tumors that are ER-positive [33].